What to Know About Orforglipron: An Investigational Oral GLP-1

Eli Lilly's investigational oral GLP-1 receptor agonist, orforglipron, is under development for type 2 diabetes and obesity treatment, with Phase 3 ACHIEVE-1 trial results showing statistically significant efficacy and a safety profile consistent with injectable GLP-1s. Lilly plans to submit orforglipron for regulatory review for weight management later in 2025 and for type 2 diabetes in 2026, with potential global launch pending trial completion and regulatory approval; results from ongoing trials focused on both type 2 diabetes and obesity are expected between late 2025 and early 2026.

Analysis

Eli Lilly (LLY) has significantly advanced its position in the metabolic disease market with the successful completion of the first Phase 3 trial, ACHIEVE-1, for its investigational oral GLP-1 drug, orforglipron. The trial demonstrated statistically significant efficacy in type 2 diabetes and, crucially, a safety profile consistent with the class of injectable GLP-1s, as published in the New England Journal of Medicine. This result de-risks a major pipeline asset. The drug's key differentiator is its once-daily oral formulation without food or water restrictions, offering a substantial convenience advantage over current injectable treatments. Lilly is moving toward commercialization with planned regulatory submissions for weight management in late 2025 and for type 2 diabetes in 2026. Further pivotal data from ongoing ATTAIN (obesity) and ACHIEVE (diabetes) trials are expected between late 2025 and early 2026, which will be critical in defining the drug's full clinical and commercial profile.

Key Decisions for Investors

• Consider the positive Phase 3 results a significant de-risking event for a key pipeline asset, reinforcing Eli Lilly's competitive moat in the high-growth GLP-1 market.
• Monitor upcoming data readouts from the ATTAIN and additional ACHIEVE trials in late 2025 and early 2026, as these are the next major catalysts that will further define the drug's market potential.
• Factor in the potential for accelerated market share capture from injectable competitors post-approval, given the substantial convenience advantage of an oral, once-daily pill.
• Acknowledge that regulatory risk remains until FDA approval, with the planned submissions in 2025 and 2026 representing key hurdles to clear before commercialization.